Combined drug sales in the five major European markets represent the second-biggest market globally after the US. Unlike the US, which is dominated by a wide range of private payers, governments are the major payers in Europe. The monopsonistic nature of these markets provides governments with significant leverage and they use extensive P&R controls to contain spiralling healthcare costs.
Scope
Evaluation of the pressures facing the drugs industry and how these pressures will impact P&R
Overview of global P&R controls, examining which are important in the European market both currently and in the future
In-depth analysis of each of the five major European markets, examining both the healthcare systems and the key P&R infrastructure
Identification of trends and recommendations shaping the European P&R environment
Highlights
Better dialogue between healthcare providers and drugs companies is vital; however, healthcare provider devolution has led to fragmentation of the key European markets, making it difficult to identify key P&R stakeholders
Many European governments profess to be willing to reward innovative drugs, however this is largely a smokescreen as debt-ridden governmental payers increasingly prioritize cost containment
European drug developers need to prioritize P&R as an important factor in drug development, and focus on securing strong P&R justification before green-lighting me-too drugs
Reasons to Purchase
Gain a clear understanding of the healthcare market dynamics and P&R environment within each of the five major European healthcare markets
Review P&R trends in Europe, based on Datamonitor's analysis and primary research conducted with key stakeholders in the industry
Gain insight into how P&R fits into company strategy and understand how specific P&R trends are shaping the European markets
(0 items)
